P. Garrido
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
P. Garrido has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Lluis Salleras
University of Barcelona
6 shared publications A. Domínguez
Department of Public Health, School of Medicine, University of Barcelona, Spain
2 shared publications- Andreu Prat
Department of Public Health, School of Medicine, University of Barcelona, Spain
2 shared publications D. Ibáñez
Department of Health, Generalitat of Catalonia, Spain
2 shared publications- E. Navas
General-Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131-159, 08028 Barcelona, Spain
2 shared publications J L Taberner
2 shared publications
Latest Publications
- 1 July 2017
- Published by Elsevier in Vacunas (English Edition)
- Vol. 18 (2) , 85-86
Book's title: Vacunas 2016 Authors: Campins Martí M, Moraga Llop FA, editors. Madrid: Undergraf; year 2016
- 1 July 2017
- Published by Elsevier in Vacunas (English Edition)
- Vol. 18 (2) , 85-86
Book's title: Vacunas 2016 Authors: Campins Martí M, Moraga Llop FA, editors. Madrid: Undergraf; year 2016
- 13 December 2012
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (5) , 647-655
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months. The cost was the sum of the cost of treating latent tuberculosis infection in all contacts plus the cost of treating tuberculosis in whom the disease was not avoided. The effectiveness was expressed as cases avoided. The efficacy adopted was 90 % for rifampin for 4 months and 93 % for isoniazid for 9 months. We carried out a sensitivity analysis for efficacies of rifampin for 4 months of 80 %, 75 %, 69 % and 65 %. Of the 1,002 patients studied, 139 were treated with rifampin for 4 months and 863 were treated with isoniazid for 9 months. The cost-effectiveness was €436,842.83/50 cases avoided with rifampin for 4 months and €692,164.42/40 cases avoided with isoniazid for 9 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies of 75 % or greater. The cost-effectiveness analysis favoured the use of rifampin for 4 months when its efficacy was 75 % or greater.
- 13 December 2012
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (5) , 647-655
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months. The cost was the sum of the cost of treating latent tuberculosis infection in all contacts plus the cost of treating tuberculosis in whom the disease was not avoided. The effectiveness was expressed as cases avoided. The efficacy adopted was 90 % for rifampin for 4 months and 93 % for isoniazid for 9 months. We carried out a sensitivity analysis for efficacies of rifampin for 4 months of 80 %, 75 %, 69 % and 65 %. Of the 1,002 patients studied, 139 were treated with rifampin for 4 months and 863 were treated with isoniazid for 9 months. The cost-effectiveness was €436,842.83/50 cases avoided with rifampin for 4 months and €692,164.42/40 cases avoided with isoniazid for 9 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies of 75 % or greater. The cost-effectiveness analysis favoured the use of rifampin for 4 months when its efficacy was 75 % or greater.
- 1 January 1994
- p. 127-31
[Advice for accident prevention].
- 30 May 1992
- Vol. 99 (1) , 6-8
[The prevalence of tetanus antibodies in the adult population of Catalonia].
The aim of this study was to know the immune state of the adult population of Catalonia (Spain) versus tetanus. The prevalence of antitetanic antibodies was determined in a representative sample (n = 604) of this population group (greater than or equal to 15 years). The technique used as that of passive hemagglutination reaction. The field work was carried out during 1989. 37.7% of the males and 15.7% of the females (p less than 0.001) presented titres of protector antibodies (greater than or equal to 0.01 Ul/ml) versus tetanus. The prevalence of antibodies was higher in youths of either sex and progressively descended with age. No statistically significant association was found upon performance of multivariate analysis between the sociodemographic variables (place of birth, level of education, residence, social class) and the prevalence of antibodies. The results of this study demonstrate that antitetanic vaccination currently being undertaken is not sufficient to insure adequate protection during adult life thus potentiating the need for the vaccination of adults in Catalonia.
- 30 May 1992
- Vol. 99 (1) , 6-8
[The prevalence of tetanus antibodies in the adult population of Catalonia].
The aim of this study was to know the immune state of the adult population of Catalonia (Spain) versus tetanus. The prevalence of antitetanic antibodies was determined in a representative sample (n = 604) of this population group (greater than or equal to 15 years). The technique used as that of passive hemagglutination reaction. The field work was carried out during 1989. 37.7% of the males and 15.7% of the females (p less than 0.001) presented titres of protector antibodies (greater than or equal to 0.01 Ul/ml) versus tetanus. The prevalence of antibodies was higher in youths of either sex and progressively descended with age. No statistically significant association was found upon performance of multivariate analysis between the sociodemographic variables (place of birth, level of education, residence, social class) and the prevalence of antibodies. The results of this study demonstrate that antitetanic vaccination currently being undertaken is not sufficient to insure adequate protection during adult life thus potentiating the need for the vaccination of adults in Catalonia.